...Fisher Scientific Inc. to develop companion diagnostics. Illumina is developing the NGS-based pan-cancer companion diagnostic TruSight Tumor 170...

...with Foundation’s 324-gene panel (R 2 = 0.95), according to Fabrizio, and with Illumina Inc.’s TruSight Tumor 170...
...profiling mutations in cell-free DNA in plasma using a 394-gene panel Illumina Inc. (NASDAQ:ILMN) (A) TruSight Tumor 170...

...Watson for Genomics to compare variant genetic data produced by TruSight Tumor 170 to published medical literature. TruSight Tumor 170...

...to standardize and simplify genomic data interpretation. Illumina will pair its cancer genome sequencing panel, TruSight Tumor 170...

...Illumina launched TruSight Tumor 170 next-generation sequencing solution to evaluate tumor biomarkers. The research use only test runs...